Endpoints News 生物医药· Kyle LaHucik·· 2026-10-01AI 评分42
Kallyope 更名 TriGemX Bio 并获 9,400 万美元资金以推进偏头痛药物 III 期试验
Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug
AI 导读
纽约市药物开发商 Kallyope 更名为 TriGemX Bio,宣布将业务重心完全转向偏头痛治疗。此举发生在与 Novo 达成肥胖症药物交易后,公司获得 9,400 万美元资金支持。该资金主要用于推进其在研偏头痛药物的 III 期临床试验。
正文
New York City drug developer Kallyope is rebranding as TriGemX Bio as it focuses solely on treating migraine.
To support the restructured company and its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news